P. Sawrycki

发表

Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer.

J. Schiller, P. Bycott, C. Twelves, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomised phase II study of axitinib or bevacizumab combined with paclitaxel / carboplatin as fi rst-line therapy for patients with advanced non-small-cell lung cancer

J. Schiller, P. Bycott, C. Twelves, 2013 .

Relationship between CYP1B1 polymorphisms (c.142C > G, c.355G > T, c.1294C > G) and lung cancer risk in Polish smokers.

A. Tretyn, K. Domagalski, Marcin Gąsior, 2018, Future oncology.

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

T. Owonikoko, P. Roberts, J. Hamm, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

J. Burke, T. Powles, T. Choueiri, 2021, The New England journal of medicine.

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.

T. Owonikoko, P. Roberts, J. Hamm, 2019 .

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.

T. Powles, T. Choueiri, S. Park, 2021 .

Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor

F. Gao, A. DeMichele, B. Melichar, 2017, EBioMedicine.

Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial

K. Venkatakrishnan, R. Kurzrock, I. Ray-Coquard, 2019, JAMA oncology.

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Fernando Maciel Barbosa, Raymond J. McDermott, J. Burke, 2022, The Lancet. Oncology.

Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564.

T. Powles, T. Choueiri, S. Park, 2022, Journal of Clinical Oncology.

Chemotherapy control by breath profile with application of SPME-GC/MS method.

Bogusław Buszewski, B. Buszewski, Agnieszka Ulanowska, 2012, Journal of separation science.

Adjuvant pembrolizumab (pembro) for renal cell carcinoma (RCC) across UCLA Integrated Staging System (UISS) risk groups and disease stage: Subgroup analyses from the KEYNOTE-564 study.

T. Choueiri, S. Park, P. Tomczak, 2023, Journal of Clinical Oncology.

Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer.

P. Bycott, L. Havel, E. Chmielowska, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.